Source: Eur Respir J 2013; 42: 590-593
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Eric D. Bateman. Tiotropium Respimat increases the risk of mortality: con. Eur Respir J 2013; 42: 590-593

Member's Comments

No comment yet.

Related content which might interest you: Tiotropium Respimat increases the risk of mortality: pro Source: Eur Respir J 2013; 42: 584-589 Year: 2013 Increased risk of mortality in COPD patients using tiotropium respimat vs. tiotropium Handihaler Source: Annual Congress 2012 - Exacerbations of asthma and COPD: assessment, impact and novel treatments Year: 2012 Use of tiotropium Respimat versus HandiHaler and mortality in patients with COPD Source: Eur Respir J 2014; 43: 1816-1818 Year: 2014 Use of tiotropium Respimat versus HandiHaler and mortality in patients with COPD Source: Eur Respir J 2014; 43: 1818-1819 Year: 2014 Lung function indices for predicting mortality in COPD Source: Eur Respir J 2013; 42: 616-625 Year: 2013 Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD Source: Eur Respir J 2013; 42: 606-615 Year: 2013 Efficacy in COPD patients of tiotropium administered via the Respimat® Soft MistÔ Inhaler (SMI) compared to HandiHaler® (HH) Source: Eur Respir J 2006; 28: Suppl. 50, 431s Year: 2006 NVA237 once daily reduces the percentage of patients with exacerbations of COPD and associated hospitalizations: The GLOW1 trial Source: Annual Congress 2011 - New treatments for airway disease Year: 2011 LATE-BREAKING ABSTRACT: Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: The SHINE study Source: Annual Congress 2012 - New drug targets and pre-clinical models for respiratory diseases Year: 2012 Dose-response to tiotropium administered via the Respimat® Soft MistÔ Inhaler (SMI) to patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 318s Year: 2006 One-year mortality associated with COPD treatment: A comparison of tiotropium and long-acting beta-2-agonists Source: International Congress 2014 – Prevalence of COPD and mortality from COPD Year: 2014 Tiotropium + olodaterol provides significant lung-function benefits compared to fluticasone + salmeterol regardless of prior bronchodilator use Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Reductions in COPD Exacerbations with Tiotropium Compared to Salmeterol Source: Annual Congress 2010 - COPD exacerbation Year: 2010 Cost effectiveness of budesonide/formoterol vs fluticasone/salmeterol: Real-world effectiveness and safety in COPD Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 Tiotropium reduces COPD exacerbations: the MISTRAL study Source: Eur Respir J 2004; 24: Suppl. 48, 513s Year: 2004 Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 AMPLIFY: efficacy of aclidinium vs tiotropium in COPD Source: International Congress 2018 – COPD management Year: 2018 Tiotropium in COPD patients Source: Breathe 2008; 5: 271 Year: 2009 Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013